For healthcare professionals only


MS drug is suspended after reports of inflammatory brain disorders

BMJ 2018; 360 doi: (Published 08 March 2018) Cite this as: BMJ 2018;360:k1114
  1. Nigel Hawkes
  1. London

The European Medicines Agency has suspended the licence of a multiple sclerosis drug after 12 reports of serious inflammatory brain disorders, three of them fatal.

Zinbryta (daclizumab) had already been withdrawn voluntarily by its manufacturers, Biogen and Abbvie. The company said that, given the nature and complexity of the adverse events being reported, as well as the limited numbers being treated with the drug, it was the right course of action. All clinical trials of daclizumab will also be discontinued. …

View Full Text

Log in

Log in through your institution


* For online subscription